• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

蛋白质和肽类的眼部递药：挑战与新制剂方法。

Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

机构信息

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.

出版信息

Adv Drug Deliv Rev. 2018 Feb 15;126:67-95. doi: 10.1016/j.addr.2018.01.008. Epub 2018 Jan 13.

DOI:10.1016/j.addr.2018.01.008
PMID:29339145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5995646/
Abstract

The impact of proteins and peptides on the treatment of various conditions including ocular diseases over the past few decades has been advanced by substantial breakthroughs in structural biochemistry, genetic engineering, formulation and delivery approaches. Formulation and delivery of proteins and peptides, such as monoclonal antibodies, aptamers, recombinant proteins and peptides to ocular tissues poses significant challenges owing to their large size, poor permeation and susceptibility to degradation. A wide range of advanced drug delivery systems including polymeric controlled release systems, cell-based delivery and nanowafers are being exploited to overcome the challenges of frequent administration to ocular tissues. The next generation systems integrated with new delivery technologies are anticipated to generate improved efficacy and safety through the expansion of the therapeutic target space. This review will highlight recent advances in formulation and delivery strategies of protein and peptide based biopharmaceuticals. We will also describe the current state of proteins and peptides based ocular therapy and future therapeutic opportunities.

摘要

在过去几十年中，蛋白质和肽对各种疾病（包括眼部疾病）的治疗产生了重大影响，这得益于结构生物化学、基因工程、制剂和给药方法方面的重大突破。由于蛋白质和肽（如单克隆抗体、适体、重组蛋白和肽）体积大、渗透性差且易降解，因此将其递送到眼部组织会面临重大挑战。为了克服频繁向眼部组织给药的挑战，人们正在广泛开发各种先进的药物传递系统，包括聚合物控释系统、基于细胞的传递系统和纳米片。预计与新的给药技术集成的下一代系统将通过扩大治疗靶标空间来提高疗效和安全性。本文综述了蛋白质和肽类生物制药制剂和给药策略的最新进展。我们还将描述基于蛋白质和肽的眼部治疗的现状和未来的治疗机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f60f3b7557f6/nihms937027f20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9d18e794a27e/nihms937027f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9ccfafa5e31c/nihms937027f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/13e8045f7c3d/nihms937027f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9d059986233c/nihms937027f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/5c23d63713d0/nihms937027f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/1018437ec76f/nihms937027f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/60614b3264a5/nihms937027f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/755f2708161c/nihms937027f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/bfef9472f299/nihms937027f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/824dc7731c11/nihms937027f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/a3a17f079d53/nihms937027f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/dfd1882471af/nihms937027f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/04d628b8b5c5/nihms937027f13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/640dbb3a47f0/nihms937027f14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f342fd0fc766/nihms937027f15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/e400e38e0803/nihms937027f16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f0877575dc87/nihms937027f17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/0cb66c0ad38c/nihms937027f18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/4380971ca0d3/nihms937027f19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f60f3b7557f6/nihms937027f20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9d18e794a27e/nihms937027f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9ccfafa5e31c/nihms937027f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/13e8045f7c3d/nihms937027f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/9d059986233c/nihms937027f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/5c23d63713d0/nihms937027f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/1018437ec76f/nihms937027f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/60614b3264a5/nihms937027f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/755f2708161c/nihms937027f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/bfef9472f299/nihms937027f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/824dc7731c11/nihms937027f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/a3a17f079d53/nihms937027f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/dfd1882471af/nihms937027f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/04d628b8b5c5/nihms937027f13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/640dbb3a47f0/nihms937027f14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f342fd0fc766/nihms937027f15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/e400e38e0803/nihms937027f16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f0877575dc87/nihms937027f17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/0cb66c0ad38c/nihms937027f18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/4380971ca0d3/nihms937027f19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c0b/5995646/f60f3b7557f6/nihms937027f20.jpg

相似文献

1
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.蛋白质和肽类的眼部递药：挑战与新制剂方法。
Adv Drug Deliv Rev. 2018 Feb 15;126:67-95. doi: 10.1016/j.addr.2018.01.008. Epub 2018 Jan 13.
2
Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery.用于蛋白质和肽可控递送的刺激响应性聚合物系统：对眼部递送的未来影响。
Molecules. 2016 Jul 30;21(8):1002. doi: 10.3390/molecules21081002.
3
A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.一种高级口腔药物输送技术的综述，该技术有助于保护和吸收蛋白质和肽分子。
Biotechnol Adv. 2014 Nov 15;32(7):1269-1282. doi: 10.1016/j.biotechadv.2014.07.006. Epub 2014 Aug 3.
4
Recent perspectives on the delivery of biologics to back of the eye.眼部后部生物制剂递送的最新观点。
Expert Opin Drug Deliv. 2017 May;14(5):631-645. doi: 10.1080/17425247.2016.1227783. Epub 2016 Sep 6.
5
A review on parenteral delivery of peptides and proteins.肽和蛋白质的肠外给药研究进展。
Drug Dev Ind Pharm. 2019 Sep;45(9):1403-1420. doi: 10.1080/03639045.2019.1628770. Epub 2019 Jun 28.
6
Nanocarriers in ocular drug delivery: an update review.眼部给药中的纳米载体：最新综述
Curr Pharm Des. 2009;15(23):2724-50. doi: 10.2174/138161209788923886.
7
Role of Nanotechnology in Delivery of Protein and Peptide Drugs.纳米技术在蛋白质和肽类药物递送中的作用。
Curr Pharm Des. 2015;21(29):4155-73. doi: 10.2174/1381612821666150901095722.
8
Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED.长效制剂策略在治疗 PSED 中用于蛋白质和肽类药物的递释。
J Control Release. 2022 Oct;350:538-568. doi: 10.1016/j.jconrel.2022.08.040. Epub 2022 Sep 2.
9
Ocular drug delivery.眼部药物递送
Expert Opin Drug Deliv. 2006 Mar;3(2):275-87. doi: 10.1517/17425247.3.2.275.
10
An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye.向眼部递送蛋白质和肽类药物的策略更新
ACS Omega. 2023 Sep 22;8(39):35470-35498. doi: 10.1021/acsomega.3c02897. eCollection 2023 Oct 3.

引用本文的文献

1
Roles of biomaterials in modulating the innate immune response in ocular therapy.生物材料在眼部治疗中调节先天性免疫反应的作用。
Front Drug Deliv. 2023 Feb 15;3:1077253. doi: 10.3389/fddev.2023.1077253. eCollection 2023.
2
Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.用于治疗眼部疾病的基于纳米医学的眼科药物递送系统
Int J Nanomedicine. 2025 Jul 21;20:9221-9249. doi: 10.2147/IJN.S532074. eCollection 2025.
3
Biodegradable Contact Lenses for Targeted Ocular Drug Delivery: Recent Advances, Clinical Applications, and Translational Perspectives.

本文引用的文献

1
Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery.用于靶向视网膜递送的自组装抗病毒前药纳米胶束的局部制剂。
Mol Pharm. 2017 Jun 5;14(6):2056-2069. doi: 10.1021/acs.molpharmaceut.7b00128. Epub 2017 May 17.
2
Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.用于眼部给药的聚合物胶束：从结构框架到近期临床前研究
J Control Release. 2017 Feb 28;248:96-116. doi: 10.1016/j.jconrel.2017.01.012. Epub 2017 Jan 11.
3
Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?
用于靶向眼部药物递送的可生物降解隐形眼镜：最新进展、临床应用及转化前景
Molecules. 2025 Jun 10;30(12):2542. doi: 10.3390/molecules30122542.
4
Comparative transcriptomic profiling of drug-metabolizing enzymes and drug transporters in rabbit ocular subtissues, liver, and duodenum.兔眼亚组织、肝脏和十二指肠中药物代谢酶及药物转运体的比较转录组分析
Drug Metab Dispos. 2025 Jul;53(7):100099. doi: 10.1016/j.dmd.2025.100099. Epub 2025 May 20.
5
Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.局部递送靶向白细胞介素-33的人单域抗体以抑制黏膜炎症。
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01305-7.
6
Hybrid NIR-responsive liposome/hydrogel platform mediating chemo-photothermal therapy of retinoblastoma enhanced by quercetin as an adjuvant.混合近红外响应脂质体/水凝胶平台介导视网膜母细胞瘤的化学-光热疗法，槲皮素作为佐剂可增强该疗法。
Theranostics. 2025 Mar 10;15(9):3995-4015. doi: 10.7150/thno.108471. eCollection 2025.
7
External stimuli-responsive drug delivery to the posterior segment of the eye.外部刺激响应性药物递送至眼后段
Drug Deliv. 2025 Dec;32(1):2476140. doi: 10.1080/10717544.2025.2476140. Epub 2025 Mar 24.
8
Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics.年龄相关性黄斑变性（AMD）：发病机制、药物靶点方法及纳米治疗学的最新进展。
Medicina (Kaunas). 2024 Oct 8;60(10):1647. doi: 10.3390/medicina60101647.
9
Reduction of pathological retinal neovascularization, vessel obliteration, and artery tortuosity by PEDF protein in an oxygen-induced ischemic retinopathy rat model.在氧诱导的缺血性视网膜病变大鼠模型中，PEDF蛋白可减少病理性视网膜新生血管形成、血管闭塞和动脉迂曲。
FASEB Bioadv. 2024 Jul 19;6(9):311-326. doi: 10.1096/fba.2024-00059. eCollection 2024 Sep.
10
Recombinant fibrous protein biomaterials meet skin tissue engineering.重组纤维蛋白生物材料适用于皮肤组织工程。
Front Bioeng Biotechnol. 2024 Aug 14;12:1411550. doi: 10.3389/fbioe.2024.1411550. eCollection 2024.
用于治疗性抗体递送的纳米颗粒：是教条还是有前途的策略？
Expert Opin Drug Deliv. 2017 Oct;14(10):1163-1176. doi: 10.1080/17425247.2017.1273345. Epub 2016 Dec 29.
4
Supramolecular PEGylation of biopharmaceuticals.生物药物的超分子聚乙二醇化
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14189-14194. doi: 10.1073/pnas.1616639113. Epub 2016 Nov 28.
5
An anti-TNF-α antibody mimetic to treat ocular inflammation.一种抗 TNF-α 抗体模拟物，用于治疗眼部炎症。
Sci Rep. 2016 Nov 22;6:36905. doi: 10.1038/srep36905.
6
Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins.蛋白质向眼后部的递送：抗血管内皮生长因子（VEGF）蛋白质的屏障、载体与稳定性
Drug Discov Today. 2017 Feb;22(2):416-423. doi: 10.1016/j.drudis.2016.10.015. Epub 2016 Nov 3.
7
Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.固体脂质纳米粒作为眼内妥布霉素递送的有前景工具：对兔子的药代动力学研究。
Eur J Pharm Biopharm. 2016 Dec;109:214-223. doi: 10.1016/j.ejpb.2016.10.006. Epub 2016 Oct 24.
8
SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.玻璃体内注射地塞米松植入剂（Ozurdex）的安全性：SAFODEX研究。高眼压症的发病率及危险因素。
Retina. 2017 Jul;37(7):1352-1359. doi: 10.1097/IAE.0000000000001369.
9
Materials and methods for delivery of biological drugs.生物药物的传递材料和方法。
Nat Chem. 2016 Oct 21;8(11):997-1007. doi: 10.1038/nchem.2629.
10
A Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis.基质内注射与前房内注射两性霉素B联合治疗重度真菌性角膜炎
J Ophthalmol. 2016;2016:3436415. doi: 10.1155/2016/3436415. Epub 2016 Sep 19.